Does pre-arthroplasty antiviral treatment for hepatitis C reduce complication rates after total shoulder arthroplasty? A matched cohort study

Austin J Ross; Bailey J Ross; Olivia C Lee; Garrett H Williams; Felix H Savoie 3rd; Michael J O'Brien; Fernando L Sanchez; William F Sherman

doi:10.1016/j.jseint.2022.07.012

Does pre-arthroplasty antiviral treatment for hepatitis C reduce complication rates after total shoulder arthroplasty? A matched cohort study

JSES Int. 2022 Aug 12;6(6):910-916. doi: 10.1016/j.jseint.2022.07.012. eCollection 2022 Nov.

Authors

Austin J Ross¹, Bailey J Ross², Olivia C Lee^{1

3}, Garrett H Williams¹, Felix H Savoie 3rd¹, Michael J O'Brien¹, Fernando L Sanchez¹, William F Sherman¹

Affiliations

¹ Tulane University School of Medicine, Department of Orthopaedic Surgery, New Orleans, LA, USA.
² Emory University School of Medicine, Department of Orthopaedics, Atlanta, GA, USA.
³ Louisiana State University School of Medicine, Department of Orthopaedic Surgery & Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA.

Abstract

Background: Hepatitis C virus (HCV) is associated with increased complications of risk after arthroplasty. The purpose of this study was to examine the impact of HCV and a pre-arthroplasty antiviral treatment on complications following total shoulder arthroplasty (TSA).

Methods: A retrospective matched cohort study was conducted using an administrative claims database. Patients who underwent TSA were identified with Current Procedural Terminology -23472 and International Classification of Diseases procedural codes. A total of 1244 HCV patients were matched 1:3 with 3732 noninfected controls across age, sex, diabetes mellitus, tobacco use, and obesity. The HCV patients with treatment before TSA were identified by claims containing antiviral drug codes. Multivariable logistic regression was used to compare rates of 90-day medical complications and prosthesis-related complications within 2 years postoperatively for (1) HCV patients vs. controls, (2) antiviral-treated HCV patients vs. controls, and (3) antiviral-treated HCV patients vs. untreated HCV patients.

Results: Patients with HCV exhibited significantly higher rates of blood transfusion (OR 2.12), acute kidney injuries (OR 1.86), inpatient readmission (OR 2.06), revision TSA (OR 1.48), dislocation (OR 1.92), mechanical complications (OR 1.39), and prosthetic joint infection (OR 1.53) compared to controls. Antiviral-treated HCV patients exhibited a significantly lower rate of myocardial infarction (OR 0.27) and comparable rates of all other complications relative to controls (all P > .05). Compared to untreated HCV patients, antiviral-treated HCV patients exhibited significantly lower rates of 90-day medical complications (OR 0.57) and prosthetic joint infection (OR 0.36).

Conclusions: HCV is associated with significantly increased complication rates after TSA. Antiviral treatment before TSA may reduce the risk of postoperative complications.

Keywords: Antiviral treatment; Hepatitis C; Postoperative complications; Reverse shoulder arthroplasty; Total joint arthroplasty; Total shoulder arthroplasty.